An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Trial Status: active
This study is conducted to determine the safety and tolerability of INCB161734 as a
single agent or in combination with other anticancer therapies.
Inclusion Criteria
≥18 years old
Locally-advanced or metastatic solid tumor with KRAS G12D mutation
For Part 1 and Part 2 Combination Groups 1 and 2: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available standard treatment to improve the disease outcome
For Part 2 Combination Groups 3 and 4: No more than 1 prior standard treatment
Cohort specific requirements as follows:
Parts 1A and 1D: Histologically or cytologically confirmed malignant solid tumor of any tissue origin
Part 1B
Disease group 1: diagnosis of PDAC and ≤ 2 prior standard systemic regimens for pancreatic cancer
Disease group 2: diagnosis of CRC
Disease group 3: diagnosis of NSCLC
Disease group 4: diagnosis of other advanced solid tumor and not part of Disease groups 1, 2 or 3
Part 1c: Confirmed diagnosis of PDAC, CRC, or NSCLC
Parts 2A and 2B
Combination 1: Diagnosis of PDAC or Diagnosis of CRC and
Prior treatment in the advanced setting with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan and
In Part 2a: ≤ 3 prior standard regimens
In Part 2b: ≤ 2 prior standard regimens
Combination 2: Diagnoses of PDAC, CRC or NSCLC
Combination Group 3 (INCB161734 in combination with GEMNabP) and Combination Group 4 (INCB161734 in combination with mFOLFIRINOX):
Diagnosis of PDAC
≤ 1 prior standard systemic regimen for pancreatic cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
Prior treatment with any KRAS G12D inhibitor
Known additional invasive malignancy within 1 year of the first dose of study drug
History of organ transplant, including allogeneic stem cell transplantation
Significant, uncontrolled medical condition
History or presence of an ECG abnormality
Inadequate organ function Other protocol-defined Inclusion/Exclusion Criteria may apply
Additional locations may be listed on ClinicalTrials.gov for NCT06179160.
